NCT01254656 - A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022 | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

HIV-1

Interventions

DRUG

lersivirine

Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily

DRUG

lersivirine

Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily

DRUG

efavirenz

Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily

DRUG

lersivirine

Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI

DRUG

lersivirine

Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI

DRUG

etravirine

Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI

Trial Locations (23)

2010

Pfizer Investigational Site, Darlinghurst

2013

Pfizer Investigational Site, Soweto

2193

Pfizer Investigational Site, Johannesburg

3004

Pfizer Investigational Site, Melbourne

4001

Pfizer Investigational Site, Durban

6903

Pfizer Investigational Site, Lugano

7925

Pfizer Investigational Site, Cape Town

8091

Pfizer Investigational Site, Zurich

9007

Pfizer Investigational Site, Sankt Gallen

10149

Pfizer Investigational Site, Torino

14050

Pfizer Investigational Site, Mexico City

20127

Pfizer Investigational Site, Milan

26030-381

Pfizer Investigational Site, Nova Iguaçu

M5G 1K2

Pfizer Investigational Site, Toronto

H2L 4P9

Pfizer Investigational Site, Montreal

H2L 5B1

Pfizer Investigational Site, Montreal

85-030

Pfizer Investigational Site, Bydgoszcz

01-201

Pfizer Investigational Site, Warsaw

0083

Pfizer Investigational Site, Pretoria

BN2 1ES

Pfizer Investigational Site, Brighton

NW3 2QG

Pfizer Investigational Site, London

SW10 9NH

Pfizer Investigational Site, London